Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs

The Journal of Veterinary Medical Science

Yasuyuki ENDO¹  Momoi YASUYUKI²  Asuka SETOGUCHI²  Munekazu NAKAICHI³  Yuko GOTO-KOSHINO⁴  Hajime TSUJIMOTO⁵  Naoki MIURA⁶  Hiroki YAMAZAKI⁷  Masashi TAKAHASHI⁷  Yu-Chang LAI⁷ 

[1] Bayside Animal Clinic, 22-9 Sakaecho, Yokohama-shi, Kanagawa 221-0052, Japan;Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan;Laboratory of Veterinary Diagnostic Imaging, Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan;Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan;Laboratory of Veterinary Radiology, Department of Veterinary Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi 753-8515, Japan;Veterinary Medical Center, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-58 Rinku-oraikita, Izumisano, Osaka 598-8531, Japan;Veterinary Teaching Hospital, Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan

关键词: dog;    lymphoma;    multidrug resistance;    toceranib phosphate;   

DOI  :  10.1292/jvms.16-0457

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

We examined whether multidrug resistant (MDR) canine lymphoma increases gene expression for platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptor 2 (VEGFR2), and c-KIT, and whether toceranib phosphate (TOC) has potential as a treatment for MDR canine lymphoma. The clinical data showed that PDGFRα expression was higher in canine subjects with MDR T-cell lymphoma than in those with untreated T-cell lymphoma, and that c-KIT expression was greater in subjects with T-cell lymphoma than in those with B-cell lymphoma. TOC monotherapy was well tolerated without serious adverse effects, and two of the five subjects that received TOC exhibited partial responses. The data presented here could contribute to the assessment of TOC-based therapy for dogs with MDR or T-cell lymphoma.

【 授权许可】

Unknown